Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEN164 open-label study in children with autism spectrum disorder
ACTRN12621000760875Phase 2Completed
- Sponsor
- Fenix Innovation Group
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NTI164 in Autism Spectrum Disorder (ASD), sponsored by Fenix Innovation Group. Primary endpoints: Change in Clinical Global Impression Scale - Improvement (CGI-I), Change in Vineland Adaptive Behaviour Scales, Third Edition (Vineland-3) Parent/Caregiver Form and 1 more. Started Jun 2021; status: completed.
02
Drugs
NTI164
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12621000760875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000760875.